[Left ventricular hypertrophy in patients treated with regular hemodialyses]

Area of Science:

• Nephrology
• Cardiology
• Internal Medicine

Background:

• Left ventricular hypertrophy (LVH) is a primary risk factor for cardiovascular morbidity and mortality in hemodialysis patients, affecting up to 75% of this population.
• Numerous factors contribute to LVH in hemodialysis patients, including arteriovenous fistula blood flow, anemia, hypertension, fluid overload, oxidative stress, and mineral metabolism disturbances.

Purpose of the Study:

• To review the pathophysiology and risk factors associated with left ventricular hypertrophy in patients undergoing hemodialysis.
• To highlight the diagnostic criteria for concentric and eccentric left ventricular hypertrophy.
• To emphasize the importance of identifying at-risk patients and implementing targeted therapies for regression of LVH.

Main Methods:

• Review of existing literature on left ventricular hypertrophy in hemodialysis patients.
• Analysis of risk factors, including hemodynamic, inflammatory, and metabolic parameters.
• Discussion of echocardiographic criteria for diagnosing left ventricular hypertrophy, including Left Ventricular Mass Index (LVMi) and Relative Wall Thickness (RWT).

Main Results:

• Left ventricular hypertrophy develops in response to chronic pressure and volume overload, progressing from adaptive to maladaptive stages.
• Specific echocardiographic parameters (LVMi >131 g/m² for men, >100 g/m² for women; RWT >0.45 for concentric) define LVH.
• Risk factor management is crucial for achieving LVH regression.

Conclusions:

• Early identification and management of risk factors are essential for preventing and treating left ventricular hypertrophy in hemodialysis patients.
• Therapeutic interventions targeting risk factors can lead to regression of LVH, thereby reducing cardiovascular events.
• Addressing LVH in hemodialysis patients significantly improves survival rates and quality of life.